What We Do

RegeneMed delivers an integrated portfolio of advanced medical technologies and implementation services designed to expand access to critical care in low- and middle-income countries. Our platforms combine breakthrough biomedical innovation with practical, scalable delivery models—ensuring that life-saving therapies can be deployed effectively in real-world settings.

RegeneMed Platforms

RegeneMed Platforms

Transforming Critical Care Where It’s Needed Most

RegeneMed is advancing a new model for global health—bringing breakthrough medical technologies to the frontlines of care in low- and middle-income countries through SHIELD (Systemic Hyper-Inflammation Elimination to Limit Death) platforms. Our platforms target the leading drivers of preventable death, including hyperinflammation and acute kidney injury, by combining precision immunomodulation with accessible organ support.

Through a portfolio of scalable innovations and targeted clinical initiatives, we are redefining what is possible for critically ill patients—delivering life-saving care where it has historically been out of reach.

SHIELD-Malaria (Systemic Hyper-Inflammation Elimination to Limit Death in Malaria)

Rewriting the Outcome for Severe Malaria

282M cases and 610K deaths annually; >94% in Africa, ~75% in children under five¹

The Challenge

Severe malaria drives organ failure through hyperinflammation, with acute kidney injury (AKI) affecting 20–40% of patients and up to 59% of children²⁻⁵. Mortality reaches 70–85% without dialysis⁶, and survivors face substantial risk of chronic kidney disease.

The Solution

SHIELD-Malaria applies Selective Cytopheretic Device–based immunomodulation to interrupt the inflammatory cascade driving organ failure, improving survival and preserving kidney function.

What We Provide

  • Deployment of SCD-integrated therapy within existing dialysis infrastructure
  • Clinical protocol development, site implementation, and operational support
  • Training for clinicians and biomedical teams
  • Biomarker-driven research and data systems
  • Partnerships with hospitals, universities, and ministries

Impact Focus

Reducing mortality from severe malaria–associated organ failure while establishing scalable models for advanced pediatric critical care.

SHIELD-MOMS (Systemic Hyper-Inflammation Elimination to Limit Death in Maternal Obstetric Morbidity & Sepsis)

Protecting Mothers. Preserving Futures.

~70% of global maternal deaths occur in sub-Saharan Africa⁷

The Challenge

Hypertensive disorders and postpartum sepsis are leading causes of maternal mortality, driven by systemic inflammation and frequently complicated by AKI. In some settings, postpartum sepsis accounts for >30% of maternal deaths⁸, and child survival declines sharply following maternal death⁹.

The Solution

SHIELD-MOMS integrates immunomodulatory therapy into maternal care pathways to reduce inflammation-driven organ injury, improve survival, and protect both mothers and newborns.

What We Provide

  • Integration of SCD therapy into maternal and dialysis care platforms
  • Clinical protocol development for obstetric populations
  • Multidisciplinary training (obstetrics, ICU, nephrology)
  • Biomarker and maternal outcomes research
  • Partnerships with referral hospitals and ministries

Impact Focus

Reducing maternal mortality and improving neonatal survival by addressing a critical gap in obstetric care.

SHIELD-Sepsis (Systemic Hyper-Inflammation Elimination to Limit Death in Sepsis)

Targeting the Biology of Critical Illness

~21.4M sepsis-related deaths annually—nearly one-third of all global deaths¹⁰

The Challenge

Sepsis is a leading cause of death globally and the most common driver of AKI in critically ill patients. Mortality in sub-Saharan Africa can exceed 40%¹¹, with AKI occurring in >50% of ICU patients¹².

The Solution

SHIELD-Sepsis targets immune dysregulation at its source, using immunomodulation to reduce hyperinflammation, limit organ damage, and improve recovery.

What We Provide

  • Deployment of SCD therapy within ICU and dialysis-supported settings
  • Integration into sepsis care protocols
  • Training for critical care and emergency teams
  • Data systems and biomarker-driven patient monitoring
  • Strategic partnerships for national scale-up

Impact Focus

Reducing mortality from sepsis-driven organ failure while strengthening critical care capacity.

SHIELD-HORIZON - Human-centered Off-grid Renal Innovation for Zero-infrastructure Operation

Dialysis Without Limits

< 10% of patients in many LMICs can access dialysis; untreated AKI mortality can exceed 70%⁶,¹³

The Challenge

AKI is a major driver of death across malaria, sepsis, and maternal illness. Dialysis is often the only life-saving treatment, yet access is severely limited due to infrastructure, cost, and electricity requirements.

The Solution

SHIELD-HORIZON expands access through scalable dialysis innovation. The Kirpa Kit—a low-cost, manual hemodialysis platform—enables treatment without electricity. Portable and battery-operated systems further extend access across health systems.

What We Provide

  • Deployment of Kirpa Kit manual dialysis platforms
  • Integration of dialysis with SCD therapy
  • Support for portable and battery-operated systems
  • Training for clinical and technical teams
  • Health system integration and sustainability planning

Impact Focus

Closing the global dialysis gap—dramatically improving survival from AKI while enabling advanced therapies at scale.

References

  1. WHO. World Malaria Report 2024 – https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2024
  2. Conroy AL et al. Severe malaria and AKI in children – https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276826/
  3. Batte A et al. AKI in severe malaria Uganda cohorts
  4. Conroy AL et al. Inflammation and AKI in malaria
  5. Olupot-Olupot P et al. Pediatric AKI malaria studies
  6. Lewington AJ et al. Global AKI mortality and access gaps – https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6103464/
  7. WHO. Maternal Mortality Fact Sheet – https://www.who.int/news-room/fact-sheets/detail/maternal-mortality
  8. Nakimuli A et al. Postpartum sepsis Uganda data
  9. Moucheraud C et al. Child mortality following maternal death
  10. Rudd KE et al. Global sepsis burden (Lancet 2020/2023 updates) – https://www.thelancet.com
  11. Jacob ST et al. Sepsis outcomes in sub-Saharan Africa
  12. Hoste EAJ et al. AKI in ICU populations
  13. Mehta RL et al. 0by25 Global AKI Initiative